Isolation and characterization of Candida spp. in Jordanian cancer patients: prevalence, pathogenic determinants, and antifungal sensitivity.

The presence of Candida spp. in the oral cavity was evaluated in 95 cancer patients (57 in-patients and 38 out-patients) and in 65 healthcare workers in Amman, Jordan. Candida carriage occurred in 72.6% of cancer patients and 33.8% of healthcare workers, with Candida albicans being the species most commonly recovered, followed by C. glabrata. In-patients were found to harbor Candida spp. at significantly higher levels than out-patients (P = 0.0044). The number of adhered C. albicans cells and the secretion of extracellular proteinase was significantly higher in the in-patient group than in the out-patient group (P = 0.0016 and 0.00007, respectively); this significant difference was not observed regarding phospholipase secretion. Antifungal sensitivity testing data suggest that isolates were most sensitive to amphotericin B and nystatin, and least sensitive to miconazole and fluconazole, which are commonly used antifungal agents in Jordan.

[1]  J. Ninane,et al.  A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  D. Williams,et al.  In vitro secreted aspartyl proteinase activity of Candida albicans isolated from oral diseases and healthy oral cavities. , 2003, Oral microbiology and immunology.

[3]  M. Schaller,et al.  Infection of human oral epithelia with Candida species induces cytokine expression correlated to the degree of virulence. , 2002, The Journal of investigative dermatology.

[4]  A. Elkarmi,et al.  Characterization of phenotype-based pathogenic determinants of various Candida albicans strains in Jordan. , 2001, Japanese journal of infectious diseases.

[5]  M. Pfaller,et al.  International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.

[6]  D. Perlin,et al.  Prospective Study of Candida Species in Patients at a Comprehensive Cancer Center , 2001, Antimicrobial Agents and Chemotherapy.

[7]  K. Abu-Elteen.  Candida albicans strain differentiation in complete denture wearers. , 2000, The new microbiologica.

[8]  W. Leung,et al.  Oral Colonization, Phenotypic, and Genotypic Profiles of Candida Species in Irradiated, Dentate, Xerostomic Nasopharyngeal Carcinoma Survivors , 2000, Journal of Clinical Microbiology.

[9]  K. Abu-Elteen.  Effects of date extract on adhesion of Candida species to human buccal epithelial cells in vitro. , 2000, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[10]  J. Peter,et al.  Emergence of Resistance of Candida albicans to Clotrimazole in Human Immunodeficiency Virus-Infected Children: In Vitro and Clinical Correlations , 2000, Journal of Clinical Microbiology.

[11]  Ronald N. Jones,et al.  Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998 , 2000, Antimicrobial Agents and Chemotherapy.

[12]  B. Hube.  Extracellular proteinases of human pathogenic fungi. , 2000, Contributions to microbiology.

[13]  W. Leung,et al.  Oral colonization, phenotypic, and genotypic profiles of Candida species in irradiated, dentate, xerostomic nasopharyngeal carcinoma survivors. , 2000, Journal of clinical microbiology.

[14]  M. Ghannoum.  Potential role of phospholipases in virulence and fungal pathogenesis. , 2000, Clinical microbiology reviews.

[15]  M. Ghannoum,et al.  Multicenter Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A Reference Method for Testing Clinical Isolates of Common and Emerging Candidaspp., Cryptococcus spp., and Other Yeasts and Yeast-Like Organisms , 1999, Journal of Clinical Microbiology.

[16]  J. Sobel,et al.  Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans , 1999, Clinical Microbiology Reviews.

[17]  C. W. Bailey,et al.  Epidemiology of Oropharyngeal CandidaColonization and Infection in Patients Receiving Radiation for Head and Neck Cancer , 1999, Journal of Clinical Microbiology.

[18]  G. Araj,et al.  Antifungal susceptibility of Candida isolates at the American University of Beirut Medical Center. , 1998, International journal of antimicrobial agents.

[19]  B. Oppenheim.  The changing pattern of infection in neutropenic patients. , 1998, The Journal of antimicrobial chemotherapy.

[20]  K. Abu-Elteen,et al.  The prevalence of Candida albicans populations in the mouths of complete denture wearers. , 1998, The new microbiologica.

[21]  J. Billé,et al.  Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group. , 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[22]  E. Anaissie,et al.  The epidemiology of hematogenous candidiasis caused by different Candida species. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Yasunori Nakamura,et al.  Oral yeasts isolated from normal subjects in three successive trials , 1997 .

[24]  J. Rex,et al.  Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine , 1995, Journal of clinical microbiology.

[25]  M. Ghannoum,et al.  Evidence implicating phospholipase as a virulence factor of Candida albicans , 1995, Infection and immunity.

[26]  J. Wingard,et al.  Importance of Candida species other than C. albicans as pathogens in oncology patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  F. Odds,et al.  CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species , 1994, Journal of clinical microbiology.

[28]  V. Lucas.  Association of psychotropic drugs, prevalence of denture-related stomatitis and oral candidosis. , 1993, Community dentistry and oral epidemiology.

[29]  E. Anaissie.  Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  E. Budtz-Jørgensen,et al.  Etiology, pathogenesis, therapy, and prophylaxis of oral yeast infections. , 1990 .

[31]  E. Budtz-Jörgensen.  Etiology, pathogenesis, therapy, and prophylaxis of oral yeast infections. , 1990, Acta odontologica Scandinavica.

[32]  Holbrook Wp,et al.  Occurrence of oral Candida albicans and other yeast-like fungi in edentulous patients in geriatric units in Iceland. , 1986 .

[33]  W. P. Holbrook,et al.  Occurrence of oral Candida albicans and other yeast-like fungi in edentulous patients in geriatric units in Iceland. , 1986, Gerodontics.

[34]  E. Poskitt,et al.  Candida in mouth or on dummy? , 1985, Archives of disease in childhood.

[35]  R. Szargel,et al.  Oral Candida in children. , 1984, Oral surgery, oral medicine, and oral pathology.

[36]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[37]  F. Staib.  Serum-proteins as nitrogen source for yeastlike fungi. , 1966, Sabouraudia.